Asuragen Overview
- Founded
- 2005
- Status
- Acquired/Merged
- Employees
- 144
- Latest Deal Type
- M&A
- Latest Deal Amount
- $215M
Asuragen General Information
Description
Developer of molecular diagnostic products designed to optimize patient management in oncology and genetic diseases. The company presents a wide range of kits and assays for genetic sequencing as well as cancer monitoring, enabling the medical community to enhance treatment outcomes through accurate data.
Contact Information
Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Other Industries
Outcome Management (Healthcare)
Other Pharmaceuticals and Biotechnology
Decision/Risk Analysis
Parent Company
Primary Office
- 2150 Woodward Street
- Suite 100
- Austin, TX 78744
- United States
+1 (512) 000-0000
Asuragen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 13-Apr-2021 | $215M | 000.00 | 00000 | Completed | Generating Revenue |
| 7. Debt - PPP | 27-Apr-2020 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 6. Later Stage VC (Series C) | 20-Mar-2013 | 00.00 | 000.00 | 00000 | Completed | Generating Revenue |
| 5. Grant | 30-Mar-2012 | 00.00 | 000.00 | Completed | Generating Revenue | |
| 4. Later Stage VC (Series C) | 11-Aug-2011 | 000 | 000.00 | 000.00 | Completed | Generating Revenue |
| 3. Grant | 08-Oct-2008 | 00.00 | 000.00 | Completed | Startup | |
| 2. Early Stage VC (Series B) | 10-Dec-2007 | $18.5M | $67.4M | 000.00 | Completed | Startup |
| 1. Early Stage VC (Series A) | 01-Jun-2006 | $48.9M | $48.9M | 000.00 | Completed | Startup |
Asuragen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series B | 00,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 00.000 | |
| Series A | 48,895,000 | $0.001000 | $1 | $1 | 1x | $1 | 55.48% |
Asuragen Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of molecular diagnostic products designed to optimize patient management in oncology and genetic diseases. The
Diagnostic Equipment
Austin, TX
144
As of 2021
000.00
0000
0000-00-00
000000&0
000.00
00000000
d exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
0000000000 00000000 (0000000000)
San Diego, CA
000
As of 0000
000.00
0000
0000-00-00
000000&0
000.00
00000000
equat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000000000 000000000
Puteaux, France
000
As of 0000
000.00
0000
0000-00-00
000000000000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAsuragen Competitors (16)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioTheranostics | Formerly VC-backed | San Diego, CA | 000 | 000.00 | 000000&0 | 000.00 |
| 000000000000 | Private Equity-Backed | Puteaux, France | 000 | 000.00 | 000000000000 | |
| 0000000000 0000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00000 | 00000000000 | |
| 0000 00 0000 | Accelerator/Incubator Backed | Houston, TX | 00 | 000000&0 | ||
| 000000 000000000 | Formerly PE-Backed | Codolet, France | 000 | 000000&0 |
Asuragen Executive Team (18)
Asuragen Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christopher Earl Ph.D | Self | Board Member | 000 0000 |
| David Sargent | Self | Board Member | 000 0000 |
| Deval Lashkari Ph.D | Telegraph Hill Partners | Board Member | 000 0000 |
| Matthew Crawford | PTV Healthcare Capital | Board Member | 000 0000 |
| Matthew McManus MD | Asuragen | President, Chief Executive Officer & Board Member | 000 0000 |
Asuragen Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAsuragen Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Growth Capital Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Merck Global Health Innovation Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| PTV Healthcare Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Southwest Middle Market M&A | Merchant Banking Firm | Minority | 000 0000 | 000000 0 | |
| State Of Texas Real Estate Fund | Real Estate | 000 0000 | 000000 0 |
Asuragen Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 000000000000 | 01-Jan-2009 | 00000 00000 00 | 000 | Biotechnology | 0000000 0000000 00.0 |
| Mirna Therapeutics | 04-Apr-2008 | Seed Round | 000 | Biotechnology | 0000000 0000000 00.0 |
Asuragen Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000 000000000000 | 01-Jan-2009 | 00000 00000 00 | 000 | Completed |
|
| Mirna Therapeutics | 04-Apr-2008 | Seed Round | 000 | Completed |